News

The trial will enrol 1,400 patients and randomise them with either NT-300, placebo (sugar pill), oseltamivir (Tamiflu) or NT-300 plus oseltamivir. The primary objectives of the study are

OMS721 works by blocking the lectin pathway of the complement system while leaving intact the classical pathway and selectively inhibits MASP-2 representing the acquired immune response to infection.

Berinert is additionally indicated for the treatment of acute HAE attacks at all body sites in adults and children in Europe. Eligible and trained patients could even self

Located in the Hangzhou Economic and Technology Area, the facility will package Merck medicines for China and the Asia Pacific region. Merck Manufacturing president and executive vice president

Insulin pens are medical plastic systems that enable diabetes sufferers to administer their regular insulin doses themselves in a pain-free procedure. Sanofi will perform the final assembly of

Various in vitro and in vivo studies validated a range of Anticalin targeted protein drug candidates designed to bind to a Daiichi’s target and thus an undisclosed payment

The trial is designed to assess the safety and efficacy profile of ixmyelocel-T administered via catheter-based injections against placebo. Aastrom Biosciences president and chief executive officer Nick Colangelo

The licensed technology leverages one of BioTime’s HyStem hydrogels for localized delivery of growth factors such as brain-derived neurotrophic factor to improve recovery from stroke. Several pre-clinical studies

These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases. The four product patents, two from China, one from Mexico and one from New